Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

99.18 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
95 96 Next >
Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom
Broadcom expanded its multi-year partnership with Telia Company to advance telecom and cloud infrastructure using VMware's product portfolio. 
Via Benzinga
Merck to Participate in the UBS Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
These stocks near 52-week lows could be ready to rebound. 
Via The Motley Fool
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results. 
Via Benzinga
Why NYSE:MRK is a Top Pick for Dividend Investors.
Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock. 
Via Chartmill
Is Merck Stock a Buy?
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better. 
Via The Motley Fool
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Summit Therapeutics Inc. aims to advance Ivonescimab, a potential breakthrough for NSCLC. The FDA's Fast Track designation boosts its U.S. clinical pathway. 
Via MarketBeat
Exposures Product Safety
Is Pfizer Stock a Bargain for Long-Term Investors?
Wall Street's bearish take on this proven innovator may not be warranted. 
Via The Motley Fool
Is It Time to Buy October's Worst-Performing Dow Jones Stocks?
The Dow finished October down slightly. Should you buy any of these blue chips? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Magnificent Stocks Under $100 to Buy in November
The price could be right for these stocks. 
Via The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
These are the kinds of stocks that can allow investors to sleep easy at night. 
Via The Motley Fool
NYSE:MRK stands out as a stock that provides good value for the fundamentals it showcases.
MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals. 
Via Chartmill
A Look Into Merck & Co Inc's Price Over Earnings
Via Benzinga
Where Will Merck Be in 5 Years?
There's a lot to like here. 
Via The Motley Fool
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with Winrevair showing promising performance. 
Via Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
Merck (MRK) Q3 2024 Earnings Call Transcript
MRK earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months. 
Via Benzinga
Merck Q3 Earnings And Revenues Top Estimates
Merck came out with quarterly earnings of $1.57 per share. 
Via Talk Markets
Merck Beats Q3 Estimates, But Lowers Annual Forecast As Gardasil Vaccine Hit By Low China Demand
Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts. 
Via Benzinga
Will Merck's Guidance Cut Prove Gruesome In The Wake Of Januvia, Gardasil Misses?
The company also reported light sales of HPV vaccine Gardasil and diabetes meds Januvia/Janumet. 
Via Investor's Business Daily
3 Dividend Stocks That Could Raise Their Payouts in November
These dividend stocks can be excellent options for buy-and-hold investors. 
Via The Motley Fool
Merck Announces Third-Quarter 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Why Is Moderna Stock Trading Higher On Monday?
Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. 
Via Benzinga
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
What Lies In Store For Healthcare ETFs In Q3 Earnings?
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades'
Pfizer shares fell 0.8% to close at $28.64 during Thursday's session. Live Nation Entertainment shares gained 1.5% to close at $116.45. 
Via Benzinga
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
The CDC recommends expanding pneumococcal vaccine eligibility to adults aged 50 and above, impacting disease prevention with Pfizer and Merck's vaccines. 
Via Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
These stocks are trading at less than 15 times their expected future profits. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
95 96 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.